|
|
(Transportation-News.com, July 14, 2018 ) Opioids are effective pain relievers, but often have the side effect of constipation. These medicines affect the gastrointestinal tract in a variety of ways. Opioids increase the amount of time it takes stool to move through the gastric system. They increase non-propulsive contractions in the middle of the small intestine (jejunum) and decrease longitudinal propulsive peristalsis - motions critical to moving food through the intestines. This results in food that fails to travel through the digestive tract. Opioids are also able to partially paralyze the stomach (gastroparesis) so that food remains in the digestive organ for a longer period of time. Additionally opioids reduce digestive secretions and decrease the urge to defecate. Symptoms of OIC include feeling and being sick, tiredness and lethargy, appetite loss, feeling depressed.
Publisher's Pharmaceutical and Healthcare latest pipeline guide Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Opioid-Induced Constipation (OIC) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
For more information about this report @ http://www.reportsweb.com/opioid-induced-constipation-oic-pipeline-review-h1-2017
The Opioid-Induced Constipation (OIC) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Opioid-Induced Constipation (OIC) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III and Phase II stages are 2, 2 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Opioid-Induced Constipation (OIC) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Opioid-Induced Constipation (OIC) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Opioid-Induced Constipation (OIC) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Opioid-Induced Constipation (OIC) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Opioid-Induced Constipation (OIC) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Opioid-Induced Constipation (OIC) (Oncology)
Request a sample copy @ http://www.reportsweb.com/inquiry&RW0001689463/sample
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Opioid-Induced Constipation (OIC) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Opioid-Induced Constipation (OIC) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Develco Pharma Schweiz AG
Ironwood Pharmaceuticals Inc
Shionogi & Co Ltd
Sucampo Pharmaceuticals Inc
Synergy Pharmaceuticals Inc
Theravance Biopharma Inc
Inquire for Report @ http://www.reportsweb.com/buy&RW0001689463/buy/2000
ReportsWeb.com
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
